Literature DB >> 2845204

Cyclic, disulfide- and dithioether-containing opioid tetrapeptides: development of a ligand with high delta opioid receptor selectivity and affinity.

H I Mosberg1, J R Omnaas, F Medzihradsky, C B Smith.   

Abstract

Tetrapeptides of primary sequence Tyr-X-Phe-YNH2, where X is D-Cys or D-Pen (penicillamine) and where Y is D-Pen or L-Pen, were prepared and were cyclized via the side chain sulfurs of residues 2 and 4 to disulfide or dithioether-containing analogs. These peptides are related to previously reported penicillamine-containing pentapeptide enkephalin analogs but lack the central glycine residue of the latter and were designed to assess the effect of decreased ring size on opioid activity. Binding affinities of the tetrapeptides were determined to both mu and delta opioid receptors. Binding affinity and selectivity in the tetrapeptide series were observed to be highly dependent on primary sequence. For example, L-Pen4 analogs displayed low affinity and were nonselective, while the corresponding D-Pen4 diastereomers were of variable affinity and higher selectivity. Among the latter compounds were examples of potent analogs in which selectivity shifted from delta selective to mu selective as the ring size was increased. The relatively high binding affinity and delta receptor selectivity observed with one of the carboxamide terminal disulfide analogs led to the synthesis of the corresponding carboxylic acid terminal, Tyr-D-Cys-Phe-D-PenOH. This analog displayed delta receptor binding selectivity similar to that of the standard delta ligand, [D-Pen2,D-Pen5]enkephalin (DPDPE), and was found to have a 3.5-fold higher binding affinity than DPDPE. All the tetrapeptides were further evaluated in the isolated mouse vas deferens (mvd) assay and all displayed opioid agonist activity. In general, tetrapeptide potencies in the mouse vas deferens correlated well with binding affinities but were somewhat lower. Receptor selectivity in the mvd, assessed by examining the effect of opioid antagonists on the tetrapeptide concentration-effect curves, was similar to that determined in the binding studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845204     DOI: 10.1016/0024-3205(88)90547-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

Review 2.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 3.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

4.  Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study.

Authors:  P Gao
Journal:  J Comput Aided Mol Des       Date:  1996-08       Impact factor: 3.686

5.  [Dmt(1)]DALDA analogues with enhanced μ opioid agonist potency and with a mixed μ/κ opioid activity profile.

Authors:  Longxiang Bai; Ziyuan Li; Jiajia Chen; Nga N Chung; Brian C Wilkes; Tingyou Li; Peter W Schiller
Journal:  Bioorg Med Chem       Date:  2014-02-19       Impact factor: 3.641

6.  N-methylated cyclic enkephalin analogues retain high opioid receptor binding affinity.

Authors:  Grazyna Weltrowska; Irena Berezowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2009-12-17       Impact factor: 2.817

7.  Cyclic enkephalins with a diversely substituted guanidine bridge or a thiourea bridge: synthesis, biological and structural evaluations.

Authors:  Engin Bojnik; Baptiste Legrand; Youness Touati-Jallabe; Elodie Mauchauffée; Nga N Chung; Peter W Schiller; Sandor Benyhe; Marie-Christine Averlant-Petit; Jean Martinez; Jean-Franćois Hernandez
Journal:  J Med Chem       Date:  2013-07-12       Impact factor: 7.446

8.  Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis.

Authors:  Irena Berezowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2009-08-20       Impact factor: 2.817

9.  Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Authors:  Jessica P Anand; Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Chem Biol Drug Des       Date:  2012-09-12       Impact factor: 2.817

10.  A Cyclic Tetrapeptide ("Cyclodal") and Its Mirror-Image Isomer Are Both High-Affinity μ Opioid Receptor Antagonists.

Authors:  Grazyna Weltrowska; Thi M-D Nguyen; Nga N Chung; JodiAnne Wood; Xiaoyu Ma; Jason Guo; Brian C Wilkes; Yang Ge; André Laferrière; Terence J Coderre; Peter W Schiller
Journal:  J Med Chem       Date:  2016-10-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.